4.4 Review

Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials

Journal

PSYCHOPHARMACOLOGY
Volume 239, Issue 6, Pages 1989-2010

Publisher

SPRINGER
DOI: 10.1007/s00213-022-06123-7

Keywords

Psychedelics; Psychedelic therapy; Clinical trials; Treatment expectations; Expectancies; Placebo effect; Masking; Recommendations

Ask authors/readers for more resources

Psychedelic research is gaining significant interest, but faces challenges such as expectancy effects and effective condition masking, which may limit interpretability of results. Recommendations for improving research rigor include enhancing masking procedures and reducing participant expectancies.
Rationale Psychedelic research continues to garner significant public and scientific interest with a growing number of clinical studies examining a wide range of conditions and disorders. However, expectancy effects and effective condition masking have been raised as critical limitations to the interpretability of the research. Objective In this article, we review the many methodological challenges of conducting psychedelic clinical trials and provide recommendations for improving the rigor of future research. Results Although some challenges are shared with psychotherapy and pharmacology trials more broadly, psychedelic clinical trials have to contend with several unique sources of potential bias. The subjective effects of a high-dose psychedelic are often so pronounced that it is difficult to mask participants to their treatment condition; the significant hype from positive media coverage on the clinical potential of psychedelics influences participants' expectations for treatment benefit; and participant unmasking and treatment expectations can interact in such a way that makes psychedelic therapy highly susceptible to large placebo and nocebo effects. Specific recommendations to increase the success of masking procedures and reduce the influence of participant expectancies are discussed in the context of study development, participant recruitment and selection, incomplete disclosure of the study design, choice of active placebo condition, as well as the measurement of participant expectations and masking efficacy. Conclusion Incorporating the recommended design elements is intended to reduce the risk of bias in psychedelic clinical trials and thereby increases the ability to discern treatment-specific effects of psychedelic therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available